Rob Fox is an accomplished executive with over two decades of experience in pharmaceutical services, specialising in commercial leadership, strategic development, and corporate growth. Throughout his career, he has held key leadership roles at Idis and Clinigen, where he made significant contributions to business development, investor relations, and corporate strategy. As a member of Clinigen’s Senior Leadership Team, Rob played a pivotal role in advancing the company’s strategic vision and operational excellence.

Currently serving as Chief Commercial Officer at tranScrip, Rob brings 21 years of expertise across diverse commercial functions. His career has been dedicated to delivering lifecycle solutions for pharmaceutical and biotech companies, addressing critical needs in oncology, CNS, infectious disease, immunology, and rare disease therapies.

Rob is known for his collaborative approach, working closely with clinical, medical, and commercial teams to ensure patients with unmet medical needs gain access to transformative medicines. He has partnered with over 15 of the top 20 global pharmaceutical companies, as well as numerous mid-sized and emerging biotech firms.

His extensive responsibilities have included leading M&A activities, driving service expansions, and supporting pharmaceutical clients throughout pre- and post-launch phases. Most recently Rob was involved in acquisitions in drug safety, market access, and regulatory services.

Rob holds a BA (Hons) in Business Economics from the University of Liverpool. His strategic insight and leadership have been pivotal in shaping innovative solutions for pharmaceutical partners, contributing to advancements in global healthcare and improved patient outcomes.